

# PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

## PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL SEARCH REPORT  
OR THE DECLARATION

(PCT Rule 44.1)

26 JAN 2005

To:  
KILBURN & STRODE,  
Attn. Bassil, Nicholas C.  
20 Red Lion Street  
London WC1R 4PJ  
UNITED KINGDOM

1 MAR 2004

Date of mailing  
(day/month/year)

01/03/2004

Applicant's or agent's file reference

P32590WO/NCB

F/E:

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/GB 03/03192

International filing date

(day/month/year)

25/07/2003

Applicant

ROSLIN INSTITUTE (EDINBURGH)

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

**Filing of amendments and statement under Article 19:**

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

**When?** The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

**Where?** Directly to the International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland  
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2  
NL-2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Barbara Klaver

*BK*

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

## INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

### What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

**The amendments must be made in the language in which the international application is to be published.**

### What documents must/may accompany the amendments?

#### Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

**The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.**

## NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:  
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:  
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:  
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or  
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:  
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

### "Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

**It must be in the language in which the international application is to be published.**

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

### Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

### Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>P32590WO/NCB</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/GB 03/03192</b>	International filing date (day/month/year) <b>25/07/2003</b>	(Earliest) Priority Date (day/month/year) <b>26/07/2002</b>
Applicant  <b>ROSLIN INSTITUTE (EDINBURGH)</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 10 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

## 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☒ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38:2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☒ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

1  
☐ None of the figures.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB 03/03192

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
As far as claims 13 to 21 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
  
1-6 9-21
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-6, 9-21 (all partially)

A nucleic acid construct comprising (i) a nucleic acid sequence encoding a member of the lipocalin protein family, and (ii) a nucleic acid sequence encoding a peptide sequence of from 5 to 250 amino acid residues; said nucleic acid construct when the lipocalin is ovine betalactoglobulin (BLG) (accession No X12817); a host cell with said nucleic acid construct; a transgenic non-human animal in which the cells of the non human animal express the protein encoded by said nucleic acid construct; the use of said nucleic acid construct for detection of a gene activation event resulting from a change in an altered metabolic status in a cell in vitro or in vivo; a method for the detection of a gene activation event in a cell in vitro or in vivo, comprising assaying a host cell stably transfected with said nucleic acid construct, wherein said ovine betalactoglobulin is heterologous to the cell in which it is expressed, or a transgenic non-human animal, whose cells expressed such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged ovine BLG reporter gene;

---

2. claims: 1-6, 9-21 (all partially)

A nucleic acid construct comprising (i) a nucleic acid sequence encoding murine major urine protein (MUP) (accession No NM 031188) and (ii) a nucleic acid sequence encoding a peptide sequence of from 5 to 250 amino acid residues; a host cell with said nucleic acid construct; a transgenic non-human animal in which the cells of the non human animal express the protein encoded by said nucleic acid construct; the use of said nucleic acid construct for detection of a gene activation event resulting from a change in an altered metabolic status in a cell in vitro or in vivo; a method for the detection of a gene activation event in a cell in vitro or in vivo, comprising assaying a host cell stably transfected with said nucleic acid construct, wherein said murine MUP is heterologous to the cell in which it is expressed, or a transgenic non-human animal, whose cells expressed such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged murine MUP reporter gene;

---

3. claims: 1-6, 9-21 (all partially)

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A nucleic acid construct comprising (i) a nucleic acid sequence encoding rat alpha-2-urinary globulin (alpha -2u) (accession number M27434) and (ii) a nucleic acid sequence encoding a peptide sequence of from 5 to 250 amino acid residues; a host cell with said nucleic acid construct; a transgenic non-human animal in which the cells of the non human animal express the protein encoded by said nucleic acid construct; the use of said nucleic acid construct for detection of a gene activation event resulting from a change in an altered metabolic status in a cell in vitro or in vivo; a method for the detection of a gene activation event in a cell in vitro or in vivo, comprising assaying a host cell stably transfected with said nucleic acid construct, wherein said rat alpha-2-urinary globulin (alpha -2u) is heterologous to the cell in which it is expressed, or a transgenic non-human animal, whose cells expressed such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged rat alpha-2-urinary globulin (alpha -2u) reporter gene;

---

## 4. claims: 7- 8 and partially 9-21

A nucleic acid construct comprising a stress inducible promoter operatively isolated from a nucleic acid sequence encoding a member of the lipocalin protein family by a nucleic acid sequence flanked by nucleic acid sequence s recognised by a site specific recombinase, or by insertion such that it is inverted with respect to the transcription unit encoding a member of the lipocalin protein family, in which the construct additionally comprises a nucleic acid sequence comprising a tissue specific promoter operatively linked to a gene encoding the coding sequence for the site specific recombinase; a host cell with said nucleic acid construct; a transgenic non-human animal in which the cells of the non human animal express the protein encoded by said nucleic acid construct; the use of said nucleic acid construct for detection of a gene activation event resulting from a change in an altered metabolic status in a cell in vitro or in vivo; a method for the detection of a gene activation event in a cell in vitro or in vivo, comprising assaying a host cell stably transfected with said nucleic acid construct, wherein said lipocalin is heterologous to the cell in which it is expressed, or a transgenic non-human animal, whose cells expressed such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged lipocalin reporter gene

---

## 5. claims: 15-16, 18 (all partially)

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

The use of a nucleic acid construct comprising a nucleic acid sequence encoding a member of the lipocalin protein family, wherein said lipocalin protein is heterologous to the cell in which it is expressed, for the detection of a gene activation event resulting from a change in altered metabolic status in a cell in vitro or in vivo; a method for the detection of a gene activation event in a cell in vitro or in vivo, comprising assaying a host cell stably transfected with a nucleic acid construct comprising a nucleic acid sequence encoding a member of the lipocalin protein family, wherein said lipocalin protein is heterologous to the cell in which it is expressed, or a transgenic non-human animal, whose cells expressed such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged lipocalin reporter gene, as far as not covered by a previous subject;

---

**6. claim: 18 (partially)**

A method for the detection of a gene activation event in a cell in vitro or in vivo, comprising assaying a host cell stably transfected with a nucleic acid construct comprising a nucleic acid sequence encoding a member of the lipocalin protein family, wherein said lipocalin protein is heterologous to the cell in which it is expressed, or a transgenic non-human animal, whose cells expressed such a construct, in which the cell or animal is subjected to a gene activation event that is signalled by expression of a peptide tagged lipocalin reporter gene, as far as not covered by a previous subject;

---



## INTERNATIONAL SEARCH REPORT

International Application No

PC 03/03192

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 C12N15/62 C07K14/47 C12Q1/68 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K G01N C12Q A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MCCLLENAGHAN M ET AL: "Insertion of a casein kinase recognition sequence induces phosphorylation of ovine beta-lactoglobulin in transgenic mice" PROTEIN ENGINEERING, vol. 12, no. 3, March 1999 (1999-03), pages 259-264, XP002259482 ISSN: 0269-2139 cited in the application	1,2,9-12
Y	the whole document	3,4
X	WO 02/053701 A (LAREYRE JEAN-JACQUES ; UNIV VANDERBILT (US); MATUSIK ROBERT J (US); OR) 11 July 2002 (2002-07-11) figure 7; example 12	1
Y		3,4
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

16 February 2004

Date of mailing of the international search report

01.03.2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Chambonnet, F

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCHLEHUBER STEFFEN ET AL: "A novel type of receptor protein, based on the lipocalin scaffold, with specificity for digoxigenin" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 297, no. 5, 14 April 2000 (2000-04-14), pages 1105-1120, XP002150338 ISSN: 0022-2836	1,3,5,9
Y	page 1112, column 1, paragraph 2 - page 1115, column 2, paragraph 4; figures 2,10,11	3,4
X	WO 00/75308 A (SKERRA ARNE ; SCHLEHUBER STEFFEN (DE)) 14 December 2000 (2000-12-14)	1,2,5
Y	the whole document	3,4
X	SUI DEXIN; WILSON JOHN E: "Interaction of insulin-like growth factor binding protein-4, Miz-1, leptin, lipocalin-typ prostaglandin D synthase, and granulin precursor with the N-terminal half of Type III -hexokinase" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 382, no. 2, 15 October 2000 (2000-10-15), pages 262-274, XP0001172430 the whole document	1
X	SUNDARAM M ET AL: "Expression, characterization and engineered specificity of rat epididymal retinoic-acid binding protein" BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 334, no. 1, 15 August 1998 (1998-08-15), pages 155-160, XP002095127 ISSN: 0264-6021 page 156, column 1, paragraph 2 - column 2, paragraph 2; figure 1 ----- -/--	1

## INTERNATIONAL SEARCH REPORT

International Application No

PC 03/03192

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCHMIDT A M ET AL: "A ZN(II)-BINDING SITE ENGINEERED INTO RETINOL-BINDING PROTEIN EXHIBITS METAL-ION SPECIFICITY AND ALLOWS HIGHLY EFFICIENT AFFINITY PURIFICATION WITH A NEWLY DESIGNED METAL LIGAND" CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 3, no. 8, August 1996 (1996-08), pages 645-653, XP001117565 ISSN: 1074-5521 page 647, column 2, paragraph 3 - page 648, column 1, paragraph 3	1
X	US 6 114 123 A (BAUGHN MARIAH R ET AL) 5 September 2000 (2000-09-05) the whole document	1,9-12
X	CROSSETT, B. ET AL.: "Transfer of a uterine lipocalin from the endometrium of the mare to the developing equine conceptus" BIOLOGY OF REPRODUCTION, vol. 59, 1998, pages 483-490, XP002259483 the whole document	1
A	WO 97/07132 A (COMMW SCIENT IND RES ORG ; WANG LINFA (AU)) 27 February 1997 (1997-02-27) the whole document	1,3,4,9
Y		3,4
Y	US 5 948 677 A (JARVIK JONATHAN W) 7 September 1999 (1999-09-07) the whole document	3,4
A	WO 98/30715 A (ISACOFF EHUD Y ; SIEGAL MICAH S (US); UNIV CALIFORNIA (US); CALIFORNIA) 16 July 1998 (1998-07-16) the whole document	1,9-21
Y		15-18
A	WO 02/01949 A (UNI DEGLI STUDI DI MILANO ; CIANA PAOLO (IT); MAGGI ADRIANA CATERINA ) 10 January 2002 (2002-01-10) the whole document	1,9-21
A	WO 99/37142 A (JORGENSEN TRINE NOERGAARD ; MICHELSEN BIRGITTE KOCH (DK); NOVONORDISK) 29 July 1999 (1999-07-29) the whole document	9-21
A	EP 1 130 086 A (DEUTSCHES KREBSFORSCH ; TPSC TECHNOLOGIES DU PROMOTEUR (FR)) 5 September 2001 (2001-09-05) the whole document	19
	-/--	

PC 03/03192

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT 03/03192

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02053701	A	11-07-2002	WO 02053701 A2	11-07-2002
WO 0075308	A	14-12-2000	DE 19926068 C1	11-01-2001
			AU 5963900 A	28-12-2000
			CA 2376638 A1	14-12-2000
			WO 0075308 A1	14-12-2000
			EP 1181368 A1	27-02-2002
US 6114123	A	05-09-2000	AU 4711400 A	02-01-2001
			CA 2375386 A1	21-12-2000
			EP 1185640 A1	13-03-2002
			JP 2003502041 T	21-01-2003
			WO 0077203 A1	21-12-2000
WO 9707132	A	27-02-1997	AU 700977 B2	14-01-1999
			AU 6696496 A	12-03-1997
			WO 9707132 A1	27-02-1997
			CA 2229540 A1	27-02-1997
			EP 0845004 A1	03-06-1998
			JP 11510683 T	21-09-1999
US 5948677	A	07-09-1999	AU 721832 B2	13-07-2000
			AU 5691998 A	03-07-1998
			EP 0961838 A1	08-12-1999
			WO 9826094 A1	18-06-1998
			US 6265545 B1	24-07-2001
WO 9830715	A	16-07-1998	AU 5090498 A	03-08-1998
			WO 9830715 A1	16-07-1998
			US 6660844 B1	09-12-2003
WO 0201949	A	10-01-2002	IT MI20001503 A1	04-01-2002
			AU 8194601 A	14-01-2002
			WO 0201949 A2	10-01-2002
			EP 1298988 A2	09-04-2003
			US 2003182676 A1	25-09-2003
WO 9937142	A	29-07-1999	AU 2512299 A	09-08-1999
			WO 9937142 A1	29-07-1999
EP 1130086	A	05-09-2001	EP 1130086 A1	05-09-2001
			CA 2400706 A1	23-08-2001
			WO 0160982 A1	23-08-2001
			JP 2003523201 T	05-08-2003
			US 2003175959 A1	18-09-2003
EP 1111387	A	27-06-2001	JP 2000146980 A	26-05-2000
			AU 750574 B2	25-07-2002
			AU 5449199 A	27-03-2000
			CA 2342897 A1	16-03-2000
			EP 1111387 A1	27-06-2001
			WO 0014543 A1	16-03-2000
WO 0231151	A	18-04-2002	AU 9683101 A	22-04-2002
			CA 2425767 A1	18-04-2002
			EP 1325128 A2	09-07-2003
			WO 0231151 A2	18-04-2002